Pharmaceutical Technology

JULY 1, 2025

How will RFK Jr’s American dream for vaccines play out? Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!

Packaging 52

Packaging Drug Development Chemotherapy Biosimilars 52

European Pharmaceutical Review

AUGUST 21, 2023

Part of this growth was driven by Arexvy, which in May 2023, became the world’s first approved RSV vaccine for older adults. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. Merck & Co Merck & Co reached third in ranking, due to 8.4

Biosimilars 98

Biosimilars Diabetes Vaccines 98

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

covered insulin product or vaccine). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. state pharmaceutical assistance programs). had Part D expenditures on or before August 16, 2022).

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105

Pharmaceutical Technology

JULY 4, 2025

How will RFK Jr’s American dream for vaccines play out? Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52